Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Journal of Neuroinflammation

Fig. 3

From: Granzyme B-inhibitor serpina3n induces neuroprotection in vitro and in vivo

Fig. 3

Two injections of 50 μg serpina3n significantly delay the onset and minimize the severity of the disease in EAE. a This representative graph shows that 50 μg of serpina3n was administered IV at day 7 post EAE induction and delayed the onset of the disease in the treated group. A second injection with the same dose of serpina3n was injected at day 20 and maintained the decreased severity of the disease. b Two injections of 50 μg of serpina3n significantly reduced the SOS in the treated group compared to the untreated control (P < 0.05). c This graph shows the modal distribution of the clinical scores. Most of the untreated control mice were severely sick at Grade 4, whereas most of the serpina3n-treated mice were below Grade 3 (P < 0.01)

Back to article page